AvidXchange Holdings Bolsa (NASDAQ: AVDX)

Últimas noticias sobre AvidXchange Holdings (NASDAQ:AVDX) Bolsa

AvidXchange Holdings

AvidXchange Holdings Inc is a provider of AP automation software and payment solutions for middle-market businesses and their suppliers. It generates the majority of its sales from Payment revenue followed by Software revenue and Services revenue. The company generates revenue in the United States.

AvidXchange Holdings, Inc. - Common Stock

AvidXchange Holdings Inc

News

Guidance

Con Edison CFO Kirk Andrews Says We Are Narrowing And Revising Our 2024 Adjusted EPS Guidance To The Upper Half Of Our Original Range

Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) sees Q4 sales of $40.000 million-45.000 million vs $50.03 million estimate.

CMBM

Cambium Networks Sees Q4 Sales $40.000M-45.000M vs $50.03M Est

SEMrush Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMR#NYSE">SEMR</a>) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.03 by 66.67 percent. The company reported quarterly sales of $97.400 million which beat the analyst consensus estimate of $96.647 million by 0.78 percent. This is a 23.73 percent increase over sales of $78.718 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

SEMR

SEMrush Hldgs Q3 2024 GAAP EPS $0.01 Misses $0.03 Estimate, Sales $97.400M Beat $96.647M Estimate

Sandstorm Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAND#NYSE">SAND</a>) reported quarterly sales of $44.700 which missed the analyst consensus estimate of $44.900 million by 100.00 percent. This is a 100.00 percent decrease over sales of $41.324 million the same period last year.

SAND

Sandstorm Gold Q3 Sales $44.700 Miss $44.900M Estimate

nLight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASR#NASDAQ">LASR</a>) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 20 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $56.13 million which beat the analyst consensus estimate of $55.27 million by 1.55 percent. This is a 10.85 percent increase over sales of $50.63 million the same period last year.

LASR

nLight Q3 Adj $(0.08), Inline, Sales $56.13M Beat $55.27M Estimate

Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) is looking for Q2 Adj EPS of $0.30-0.40 vs $0.27 analyst estimate. sees sales of $380.000 million-400.000 million vs $354.32 million estimate.

LITE

Lumentum Holdings Sees Q2 Adj EPS $0.30-0.40 vs $0.27 Est; Sees Sales $380.000M-400.000M vs $354.32M Est

Consolidated Edison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>) reported quarterly earnings of $1.68 per share which beat the analyst consensus estimate of $1.62 by 3.7 percent.

Consolidated Edison Q3 2024 Adj. EPS $1.68 Beats $1.62 Estimate

PDF Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDFS#NASDAQ">PDFS</a>) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.20 by 25 percent. The company reported quarterly sales of $46.409 million which beat the analyst consensus estimate of $46.196 million by 0.46 percent. This is a 9.58 percent increase over sales of $42.350 million the same period last year.

PDFS

PDF Solutions Q3 2024 Adj. EPS $0.25 Beats $0.20 Estimate, Sales $46.409M Beat $46.196M Estimate

TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) affirms FY2024 sales outlook from $74.50 million-76.50 million to $74.50 million-76.50 million.

TELA

TELA Bio Affirms FY2024 Sales Guidance from $74.50M-76.50M to $74.50M-76.50M

Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) affirms FY2025 Product sales outlook from $450.00 million-475.00 million to $450.00 million-475.00 million.

IOVA

Iovance Biotherapeutics Affirms FY2025 Product Sales Guidance from $450.00M-475.00M to $450.00M-475.00M

Collegium Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLL#NASDAQ">COLL</a>) raises FY2024 sales outlook from $580.00 million-595.00 million to $620.00 million-635.00 million.

COLL

Collegium Pharmaceutical Raises FY2024 Sales Guidance from $580.00M-595.00M to $620.00M-635.00M  VS Est.625.37M

CPAY

Corpay Expects Q4 Total Revenues Of $1.04B - $1.07B, Adjusted EP Of $5.25 - $5.45

Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) affirms FY2024 Product sales outlook from $160.00 million-165.00 million to $160.00 million-165.00 million.

Iovance Biotherapeutics Affirms FY2024 Product Sales Guidance from $160.00M-165.00M to $160.00M-165.00M

AerSale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLE#NASDAQ">ASLE</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.05 by 20 percent. This is a 33.33 percent increase over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $82.68 million which missed the analyst consensus estimate of $92.83 million by 10.93 percent. This is a 10.60 percent decrease over sales of $92.48 million the same period last year.

ASLE

AerSale Q3 Adj $0.04 Misses $0.05 Estimate, Sales $82.68M Miss $92.83M Estimate

Amprius Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NYSE">AMPX</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. The company reported quarterly sales of $7.855 million which beat the analyst consensus estimate of $4.215 million by 86.37 percent. This is a 180.74 percent increase over sales of $2.798 million the same period last year.

AMPX

Amprius Technologies Q3 2024 GAAP EPS $(0.10) Beats $(0.13) Estimate, Sales $7.855M Beat $4.215M Estimate

Identiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVE#NASDAQ">INVE</a>) sees Q4 sales of $6.000 million-6.300 million vs $5.95 million estimate.

INVE

Identiv Sees Q4 Sales $6.000M-6.300M vs $5.95M Est

Fourth Quarter 2024 Outlook
For the fourth quarter 2024, the Company expects:
<ul>
<li>Revenue growth on a constant currency basis in the range of 10.3%-13.3%. This represents revenue in the range of $375-$385 million, assuming FX rates remain relatively stable with the end of Q3.&nbsp;</li>
<li>Adjusted EBITDA in the range of $9-$14 million, representing an Adjusted EBITDA Margin in the range of 2.4%-3.6%.&nbsp;</li>
</ul>

WBTN

WEBTOON Entertainment Sees Q4 Revenue Growth On A Constant Currency Basis In The Range Of 10.3%-13.3% ($375M-$385M) Vs $375.92M Est.

Tidewater Sees 2024 Revenue $1.33B-$1.35B vs $1.39B Est.

Innodata (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.13 by 169.23 percent. The company reported quarterly sales of $52.224 million which beat the analyst consensus estimate of $36.113 million by 44.61 percent. This is a 135.57 percent increase over sales of $22.169 million the same period last year.

INOD

Innodata Q3 2024 Adj. EPS $0.35 Beats $0.13 Estimate, Sales $52.224M Beat $36.113M Estimate

ABNB

Airbnb Sees Q4 2024 Revenue $2.39B-$2.44B Vs $3.717B Est.

Narrows FY24 revenue view to $437M-$439M from $436M-$439M, consensus $437.22M. Published first on TheFly – the ultimate source for real-time, marke...

AvidXchange sees FY24 adjusted EPS 24c-25c, consensus 25c

AvidXchange Non-GAAP EPS of $0.07 in-line, revenue of $112.8M beats by $1.98M

AvidXchange Holdings, Inc. (AVDX) Q3 2024 Earnings Call Transcript

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Trump Media (DJT) jumps after Donald T...

Trump Media, broader market surge after Trump wins election: Morning Buzz

Avidxchange Holdings, Inc. ( ($AVDX) ) has released its Q3 earnings. Here is a breakdown of the information Avidxchange Holdings, Inc. presented to...

AvidXchange Reports Strong Q3 2024 Financial Performance

In a report released today, Ramsey El Assal from Barclays maintained a Buy rating on AvidXchange Holdings (AVDX – Research Report), with a price ta...

Barclays Sticks to Their Buy Rating for AvidXchange Holdings (AVDX)

KeyBanc analyst Alex Markgraff maintained a Buy rating on AvidXchange Holdings (AVDX – Research Report) today. The company's shares closed yesterda...

KeyBanc Sticks to Their Buy Rating for AvidXchange Holdings (AVDX)

Piper Sandler analyst Brent Bracelin raised the firm's price target on AvidXchange (AVDX) to $10 from $9 and keeps a Neutral rating on the shares. ...

AvidXchange price target raised to $10 from $9 at Piper Sandler

As previously reported, Compass Point analyst Dominick Gabriele upgraded AvidXchange (AVDX) to Buy from Neutral with a price target of $15, up from...

AvidXchange upgraded to Buy at Compass Point on 'Street high' FY26 view

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

JPMorgan, Five Below downgraded: Wall Street's top analyst calls

AAPL

ALGM

AVDX

CBOE

CELH

CROX

CTKB

DLTR

EXAS

FIVE

HNDAF

HNHAF

HNHPF

HUBS

IRBT

NTDOF

NTDOY

PACS

PLNT

RVLV

SMCI

SNOW

SRPT

STLA

TEVA

TNGX

TRMB

VANI

ZYME

Press Releases

AvidXchange and Workamajig Announce Exclusive Strategic Partnership to Empower Media Companies to Manage Invoices Seamlessly

AVDX Investigation: Kessler Topaz Meltzer & Check, LLP Encourages AvidXchange Holdings, Inc. (NASDAQ: AVDX) Investors with Significant Losses to Contact the Firm

Comments

AvidXchange Holdings

Noticias

Últimas noticias sobre AvidXchange Holdings (NASDAQ:AVDX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL